Articles related to Hematology/Oncology

Researchers reported the finding—the longest known CLL remission after CAR T-cell therapy—in Nature. The patients received an infusion of genetically engineered autologous T cells as part of a phase 1 clinical trial in 2010.

This meta-analysis examined 1,212 published articles and abstracts, of which the 30 fulfilling their criteria were analyzed to evaluate the effect of vitamin D levels on OS, PFS, and secondarily on time to treatment, relapse rate, and non-relapse mortality in patients with hematologic malignancies. Lower vitamin D level at diagnosis was related to a significantly impaired prognosis for myeloid and lymphoid malignancies, as previously reported.

Patients with T-LL had significantly improved EFS and OS with bortezomib on the AALL1231 backbone. Systemic therapy intensification allowed elimination of CRT in more than 90% of patients with T-ALL without excess relapse. There was no difference in rates of receiving CRT.

Matthew Lunning, DO, Associate Vice Chair of Research at the University of Nebraska Medical Center, reviews treatment implications of emerging research in CAR T-cell therapy for a variety of lymphomas subtypes, and discusses newer study outcomes, limitations to current CAR-T cell products, the state of allogenic CAR-T cell therapy, and key elements to consider when selecting therapy for a given patient.

The authors analyzed a cohort of nearly 5,000 patients with AML for the prevalence and prognostic impact of IDH mutations and found distinct clinical and co-mutational features of the IDH1-R132C mutation. The study identified variable outcomes associated with distinct mutations of IDH and offers additional evidence in support of delineating the IDH2-R172K mutation as a distinct entity based on its co-mutational landscape and significant impact on outcome.

The authors analyzed the outcome of 349 patients with primary or secondary myelofibrosis undergoing reduced intensity transplantation, of whom 35 had accelerated-phase myelofibrosis. After a median follow-up of 5.9 years, estimated 5-year overall survival was between the two groups, and median overall survival was not reached. In terms of relapse, five-year incidence was 30% for the accelerated-phase group versus 15% for the chronic-phase group. Reduced intensity transplantation showed excellent survival but higher relapse for accelerated-phase myelofibrosis.